Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emtricitabine/tenofovir alafenamide - Gilead Sciences

Next Previous
Drug Profile

Emtricitabine/tenofovir alafenamide - Gilead Sciences

Alternative Names: DESCOVY; Descovy; F/TAF; Tenofovir alafenamide/emtricitabine

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Clinton Health Access Initiative; Gilead Sciences; Japan Tobacco; National Institute of Allergy and Infectious Diseases; PENTA Foundation
  • Class Antiretrovirals; Deoxyribonucleosides; Purines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 19 Dec 2023 University of Washington and Gilead Sciences completes a Phase-II/III clinical trials in HIV-1 infections (Prevention) in Kenya (PO) (NCT05140954)
  • 13 Jul 2023 Gilead Sciences, Clinton Health Access Initiative and Penta agree to co-develop dispersible paediatric fixed dose formulation of emtricitabine/tenofovir alafenamide for HIV infections (In children)
  • 13 Jul 2023 Preclinical trials in HIV-1 infections in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top